http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Precision Oncology Diagnostics Leader, Cancer Genetics, Inc. & Precision Therapeutics Company, Lantern Pharma, Inc. Announce Strategic Collaboration Focused on Drug Rescue & Repurposing Levera
-
Cancer Genetics (CGIX) Reports Multiple Agreements, Collaborations for Liquid Biopsy Programs
-
Cancer Genetics, Inc. Announces Multiple Agreements & Collaborations to Develop Liquid Biopsy Programs with Leading Biopharma Companies
-
Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics
-
Merck (MRK) Lists Cancer Genetics (CGIX) as KEYTRUDA National Reference Laboratory
-
Cancer Genetics, Inc. Listed by Merck as a National Reference Laboratory for KEYTRUDA® (pembrolizumab) Companion Diagnostic Testing
-
Cancer Genetics, Inc. and Leading Collaborators to Present Innovative Insights That Will Advance Precision Medicine in Diffuse Large B-cell Lymphoma (DLBCL) at American Society of Hematology (ASH) Ann
-
Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year Revenue Growth and Highlights Path to Future Profitability
-
Cancer Genetics, Inc. to Report Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016
-
Cancer Genetics (CGIX) Announces Launch of Focus::Renal
-
Cancer Genetics, Inc. Launches Focus::Renal™, a Unique, Comprehensive and Highly Sensitive Next Generation Sequencing (NGS) Panel for Enabling Precision and Personalized Medicine in Renal Cancers
-
Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock Conference on October 20
-
Pre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...)
-
Cancer Genetics (CGIX), ApoCell Enter Strategic Partnership for Circulating Tumor Cells
-
Cancer Genetics, Inc. and ApoCell Announce Partnership Focused on Transforming Cancer Profiling & Therapy Selection Leveraging Proprietary, High-Performance, Liquid Biopsy Platform for Rare Cell C
-
Cancer Genetics, Inc. to Present at Two Upcoming Investor Conferences During September
-
Cancer Genetics (CGIX), BARC Enter Partnership for Clinical Trials
-
Cancer Genetics, Inc. Announces a Global Partnership with BARC Global Central Laboratory to Offer Comprehensive Clinical Trial and Companion Diagnostic Solutions for the Oncology Industry
-
Cancer Genetics (CGIX) Enters 2.75M Share Registered Direct Offering
-
Cancer Genetics Announces $5.5 Million Registered Direct Offering
-
Cancer Genetics, Inc. to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
-
Cancer Genetics' (CGIX) Focus::Myeloid NGS-Based Panel Receives Approval in New York State
-
Cancer Genetics, Inc. Strengthens Position as a Leader in Myeloid Cancer Diagnosis and Management Receiving New York State Approval for Focus::Myeloid™, a Targeted NGS Panel for Improved Diagnosis,
-
Cancer Genetics to Report Second Quarter Earnings on Wednesday, August 10
-
Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker Discovery and Testing for a Global Drug Development Program in Hematologic Cancers
-
Cancer Genetics' (CGIX) Focus::CLL Approved in New York State
-
Cancer Genetics, Inc. Receives New York State Approval for Focus::CLL™, a Unique NGS Panel for Chronic Lymphocytic Leukemia, Reinforcing the Company’s Market-Leading Position in the Diagnosis and
-
Cancer Genetics (CGIX) Begins Offering VENTANA PD-L1 as Complimentary IHC Test for TECENTRIQ
-
Cancer Genetics, Inc. Expands Its Immuno-Oncology Franchise With The Addition of The FDA-Approved VENTANA PD-L1 (SP142) Assay As A Complementary Diagnostic Test For TECENTRIQ™
-
Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance
-
Cancer Genetics (CGIX) Enters Distribution Agreement for TOO Test in India, South Asia
-
Cancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI’s Proprietary FDA-cleared Tissue of Origin (TOO®) Test Throughout India and South Asia
-
Cancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference
-
HTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
-
Cancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma ™
-
Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
-
Cancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC
-
Cancer Genetics (CGIX) Actively Testing, Providing Data for 12 IO Clinical Trials, 3 Academic Collaborations
-
Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active Clinical Trials In Progress With Leading Biotech and Pharma Companies
-
Cancer Genetics to Report First Quarter 2016 Financial Results on Tuesday, May 10th
-
Cancer Genetics, Inc. to Present at 28th Annual ROTH Conference on March 16, 2016
-
Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
-
Cancer Genetics, Inc. Launches Next Generation Sequencing Panel for Diagnosis & Treatment Selection in Solid Tumors, CGI FOCUS::Oncomine™
-
Cancer Genetics to Report Fourth Quarter & Fiscal 2015 Financial Results on Thursday, March 10
-
Cancer Genetics, Inc. to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
-
Cancer Genetics (CGIX) Enters in-Network Provider Agreement with BCBS of Minnesota
-
Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
-
Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients
-
Cancer Genetics, Inc. (CGI) to Present Results of Collaborative Renal Biopsy and Clear Cell Renal Cell Carcinoma (ccRCC) Studies at the 2016 Genitourinary Cancer Symposium
-
Cancer Genetics, Inc. to Present at Piper Jaffray 27th Annual Healthcare Conference on December 2nd

